Print this page    •   Back to Web version of article

New Anti-HIV Drugs Receive FDA Approval

October 2003

Three anti-HIV drugs have recently been approved by the Food and Drug Administration, including one in a new class called fusion or entry inhibitor. Each adds something unique to the arsenal of therapies to treat HIV infection. The three include:


Drug NameTrade NameCompanyDrug Class
T-20, enfuvirtideFuzeonHoffman La-Roche, Trimerisentry inhibitor
FTC, emtricitabineEmtrivaGileadnucleoside analog reverse transcriptase inhibitor
AtazanavirReyatazBristol-Myers Squibbprotease inhibitor


The following articles highlight information on each of the newly approved drugs and provide a discussion on how they fit into the arsenal of existing drugs.


Back to the Project Inform Perspective October 2003 contents page.




This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art5497.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.